2Kirsti Hallsten, Kirsi A Virtanen, Fredrik Lannqvist, et al. Rosiglitazone but not metformine enhances insulin - and exercise- stimulated skeletai muscle glucose uptake in patients with newly diagnosed type 2 diabetes.Diabetes,2002,51:3479 - 3485.
3Basile DP. Transforming growth factor - beta as a target for treament in diabeic nephropathy. Am J Kidney Dis,2001,38(4) :887 - 892.
4Fonseca V, Biswas N, Salzmzn A. Once daily rosiglitazone in combination with meyformin effectively reduces hyperglycemia in patient with 2 diabetes. Diabetes, 1999,48(2): 100 - 110.
5Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab, 2001,27:305.
6Glaser V. New criteria for diagnosis, screening and classification. Patient Care, 1998, (2): 12 - 32.
7Laakso M.Dyslipidemia,morbidity,and mortality in non-insulindependent diabetes mellitus.Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus.J Diabetes Complications,1997,11(2):137-141.
8Bonnet F,Cooper ME.Potential influence of lipids in diabetic nephropathy:insights from experimental date and clinical studies.Diabetes Metab,2000,26(4):254.
9Hirano T.Lipoprotein abnormalities in diabetic nephropathy.Kidneys Int,1999,71 (Suppl):s22-s24.
10Bahl VK,Vaswani M,Thatai D,et al.Plasma levels of apoliproteins A-1 and B in Indian patients with angiographically defined coronary artery disease.Int J Cardiol,1994,46(2):143-149.
